Business
Contineum Therapeutics to Attend Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)-- Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on
About this update from Contineum Therapeutics, Inc.
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nContineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to attend the following investor conferences during November 2024.\n\n\n\nStifel 2024 Healthcare Conference, Monday, November 18, 2024, New York - Carmine Stengone, Contineum’s President and CEO, will present at 4:10 p.m. ET.\n\n\n\nJefferies 2024 London Healthcare Conference, Thursday, November 21, 2024, London - Company management will participate in one-on-one meetings.\n\n\n\nThe Stifel presentation will be webcast on the Investors section of Contineum’s website. A webcast replay will also be available.\n\n\nAbout Contineum Therapeutics\n\n\nContineum Therapeutics (Nasdaq: CTNM) is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Contineum is focused on targeting biological pathways associated with specific clinical impairments, that Contineum believes, once modulated, may demonstrably impact the course of disease. Contineum has a pipeline of internally-developed programs to address multiple NI&I disorders. Contineum has two drug candidates in clinical trials, PIPE-791, an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis and progressive multiple sclerosis, and PIPE-307, a selective inhibitor of the M1 receptor in clinical development for relapsing-remitting multiple sclerosis. PIPE-307 is being developed pursuant to a global license and development agreement between Contineum and Janssen Pharmaceutica NV, a Johnson & Johnson company, who has also announced plans to initiate a Phase 2 trial of PIPE-307 in depression in 2024. For more information, please visit www.contineum-tx.com.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20241113433403/en/\n\nSteve Kunszabo\nContineum Therapeutics\nSenior Director, Investor Relations & Corporate Communications\n858-649-1158\[email protected]\n\n\nSource: Contineum Therapeutics, In...